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Abstract
The gene therapy strategy of mutation compensation is designed to rectify the molecular
lesions that are etiologic for neoplastic transformation. For dominant oncogenes, such
approaches involve the functional knockout of the dysregulated cellular control pathways
provoked by the overexpressed oncoprotein. On this basis, molecular interventions may be
targeted to the transcriptional level of expression, via antisense or ribozymes, or post-
transcriptionally, via intracellular single chain antibodies (intrabodies). For carcinoma of the
breast, these approaches have been applied in the context of the disease linked oncogenes
erbB-2 and cyclin D1, as well as the estrogen receptor. Neoplastic revision accomplished in
modal systems has rationalized human trials on this basis.
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Introduction
The gene therapy approach of mutation compensation
involves correction of the genetic lesions that are etio-
logic for neoplastic transformation [1•,2–4]. For the domi-
nant oncogene type of genetic lesion, such genetic
correction approaches are designed to functionally ablate
dysregulated patterns of gene expression. In considering
this type of gene therapy approach for breast cancer,
knowledge of the genetic mechanisms responsible for ini-
tiation and progression of malignancy is of relevance. In
this regard, breast cancer, like other types of human
cancer, develops via a succession of genetic alterations
[5–7]. Inherited or somatic genetic changes that occur in
oncogenes, tumor suppressor genes, the DNA repair
machinery, and cell cycle checkpoints lead to low-risk or
high-risk forms of in situ carcinoma, and subsequently to
invasion and metastasis. For colorectal carcinoma, such
changes have been well enumerated by Vogelstein and
coworkers [8,9].
A similar analysis of these genetic changes in breast
cancer represents a daunting task, because of the greater
genetic heterogeneity that characterizes carcinoma of the
breast and because few of the relevant genes appear to
cause familial syndromes. In this regard, potentially, func-
tional analysis of gene products that are known to be
involved in breast cancer (eg p53, Rb, p16, BRCA-1,
BRCA-2, ATM), combined with further characterization of
other loci implicated by allelic loss or gene amplification,
will lead to the identification of pathways that are impor-
tant to the pathogenesis of many or all breast cancers.
Such an understanding of the molecular pathogenesis of
breast cancer will allow rational application of novel gene
therapeutic and pharmacologic strategies for adjuvant
therapy and the early treatment of recurrence.
On this basis, it may be understood that genetic ablation
gene therapy strategies may be most successful when such
strategies are designed to correct one, or more, of the spe-Breast Cancer Research    Vol 2 No 1 Curiel
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cific genetic changes known a priori to be present in tumor
cells. Many of these changes, including gene amplification,
allelic loss, p53 mutation, and increased expression of
certain oncogenes, are found in preinvasive lesions such as
ductal carcinoma in situ of the breast [10–15]. Early correc-
tion of these defects could prevent subsequent progression
of invasion and metastasis. Indeed, such gene therapy
approaches for precancer have been attempted in the
context of carcinoma of the lung, and are clearly relevant in
the context of carcinoma of the breast also [16]. In addition,
targeting of the same alterations in more advanced tumors
could prove effective in supplementing current therapies:
surgery, radiotherapy, and chemotherapy.
Genetic abnormalities in breast cancer
Two major forms of genetic alteration in breast cancer are
loss of specific chromosome arms and gene amplification.
Loss of heterozygosity analysis of polymorphic DNA
markers have implicated chromosomes and subregions of
chromosome arms that probably harbor tumor suppressor
genes [7]. Nonetheless, in only a few cases have specific
genes relevant to allelic loss been identified. Karyotype
analysis and chromosome in situ hybridization
approaches, such as comparative genomic hybridization
or fluorescent in situ hybridization, point to amplified chro-
mosomal loci likely to harbor oncogenes, and facilitate
loss of heterozygosity studies by identifying regions of the
genome that are under-represented in tumors [6,17–21].
These studies have shown that breast cancers are
unusual among human tumors because of their great
degree of genetic heterogeneity, suggesting that breast
cancer in reality results from multiple genetic changes.
Although characterization of the many unidentified genes
that are relevant to allelic loss and gene amplification will
undoubtedly suggest additional gene therapy strategies
for breast cancer, current knowledge of a few such targets
already offers the possibility of effective intervention.
The genetic heterozygosity of breast cancer may thus
predicate gene therapy approaches that are targeted to
multiple dysregulated alleles. In this regard, the genetic
heterogeneity of breast cancer is reflected in the various
oncogenes previously implicated. Genetic alteration
involving known oncogenes is restricted to six loci that
undergo gene amplification. No known genes, including
the ras family members, have been shown to undergo
base mutation or translocation in primary human breast
cancer. Gene amplification occurs at the following spe-
cific loci at the approximate frequencies indicated: erbB-2
(chromosome 17q12, 20% of tumors), c-myc (8p24,
20%),  PRAD1/CYD1 (11q13, 15%), the fibroblast growth
factor receptors (8p12, 10–15%), BEK (10q26, 10–15%),
and the insulin-like growth factor receptor (IGF)
(15q24-25, 2%). It also involves unidentified genes at
chromosomes 13q31, 17q22-24, and 20q12-13.2 [19,20].
In addition to these, other potential oncogenes that are
expressed in the absence of genetic alteration include H-
ras,  erbB-1/epidermal growth factor receptor (EGFR),
erbB-3, and others. Thus, a variety of candidate onco-
genes have been identified that might be approached via
genetic ablation strategies.
With the exceptions of c-myc and PRAD1/CYD1 (encod-
ing the kinase-associated cyclin D1), gene amplification in
breast cancer commonly involves one of several growth
factor receptors, as noted above. Although the signal
transduction mechanisms of these diverse molecules are
currently under study, it is likely that common elements of
the signaling machinery are involved. For example, signal-
ing by p185c-ErbB-2/1(ErbB-2) utilizes downstream elements
such as phospholipase C-g, phosphatidylinositol 3-kinase,
guanosine triphosphatase-activating protein, and the
adapter protein SHC [22]. Gene therapeutic modulation
of the basal signal transduction apparatus could therefore
prove effective in a majority of breast cancer cases. Thus,
despite the molecular heterogeneity, common points of
dysregulation can provide a limited set of rational targets.
Genetic ablation strategies for breast cancer
In this regard, the dysregulation of oncogenes by muta-
tion, gene amplification, gene rearrangement, or over-
expression contributes to oncogenesis by removing
controls on normal cell cycle regulation. One approach to
gene therapy for breast cancer is to ‘knockout’ dominant
oncogenes and thereby reduce the growth or invasive
potential of the tumor. Inhibition or ablation of oncogenic
function can occur at three levels. First, the translation of
the oncogene can be targeted. This strategy involves the
use of antisense molecules to sequester and/or function-
ally ablate oncogene messenger RNA. Second, the func-
tion of the gene product can be targeted. This approach
uses polypeptides containing dominant interfering muta-
tions (‘dominant-negative’) to downregulate signal trans-
duction in tumor cells. Third, the nascent oncogenic
protein can be prevented from reaching its proper intracel-
lular location. This approach uses intracellular antibodies
(‘intrabodies’) to pre-empt the cellular localization machin-
ery and sequester growth factor receptors inside the cell.
Antisense molecules
With regard to antisense inhibition of oncogene function,
early studies demonstrated inhibition of lymphoma growth
by administration of naked antisense DNA to c-myc [23].
Somewhat more recently, a myc antisense phosphoro-
thioate oligonucleotide that has enhanced stability has
been shown to produce cytostatic effects in estrogen-
dependent and estrogen-independent breast cancer cell
lines [24]. As an alternative approach to delivering anti-
sense molecules, inhibition of K-ras expression and its nor-
mally potent tumorigenicity was achieved in nonsmall cell
lung cancer cells in vitro through the use of a mammalian
plasmid vector that produces antisense RNA oligo-47
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nucleotides [25]. The same investigators showed a dra-
matic reduction in tumor growth in nude mice [26]. Addi-
tional genes relevant to breast cancer have been
successfully targeted by antisense oligonucleotides. Anti-
sense molecules to cyclin Di inhibited growth and
reversed the transformed phenotype in esophageal cancer
cells [27], antisense RNA to type 1 IGF receptor sup-
pressed rat prostate tumor growth and invasion [28], and
transforming growth factor-a antisense messenger RNA
inhibited estrogen-induced proliferation in estrogen
responsive breast cancer cells [29]. In addition, antisense
approaches have been developed targeting the ErbB-2
oncoprotein. In those studies, antisense oligonucleotides
delivered in vitro to breast cancer cell lines could accom-
plish downregulation of ErbB-2 with modest inhibition of
cellular proliferation [30]. In addition, the adenoviral
protein E1A has also been shown to allow selective
ErbB-2 downmodulation with reversion of the transformed
phenotype [31–33].
In the context of clinical trials, a messenger RNA antisense
approach for breast cancer is being entered into human
trials in a protocol by Arteaga and Holt [34•], which uses
disabled mouse mammary tumor virus to drive the tissue-
specific expression of antisense oligonucleotides to c-fos
and c-myc in late-stage breast cancer patients with lung,
meningeal or peritoneal metastases. These investigators
have shown that delivery of this vector encoding antisense
to c-fos results in inhibition of breast tumor growth and
increased survival in a mouse model. Similarly, the E1A
approach has been translated into the clinical context [35].
The use of antisense oligonucleotides must overcome
several obstacles in order to be clinically useful. These
include attaining stable intracellular levels by frequent
administration or by constant production internally, and the
need to inhibit oncogenes that are amplified or expressed
at high levels. As for other therapeutic approaches, the
molecule must be delivered to nearly every tumor cell in
order to be effective in inhibiting growth or invasive poten-
tial. Thus, the enthusiasm for antisense approaches to
human gene therapy trials has been limited.
Dominant negative mutations
A second approach to ablation of oncogene function is
expression of dominant interfering or ‘dominant negative’
mutant proteins. Especially attractive targets for such an
approach are the receptor tyrosine kinases (eg
ErbB-1/EGFR, ErbB-2, and ErbB-3), which appear to be
amplified and/or overexpressed in breast cancer. Two dif-
ferent mechanisms have proved effective in blocking
receptor function. One approach disrupts dimerization,
which is required for intracellular signaling. This was
accomplished by transfection of cytoplasmic domain
mutants of EGFR into cells expressing wild-type receptor.
The resulting heterodimers failed to show high affinity EGF
binding, receptor endocytosis, or biological signaling [36].
Alternatively, growth factor binding to the receptor can be
prevented by expression of a mutant growth factor, or by
sequestering the growth factor extracellularly. NIH3T3
cells that produced a mutant platelet-derived growth
factor molecule showed a reverted phenotype with a
reduced growth rate in culture, and reduced invasive
potential [37]. Extracellular sequestering was demon-
strated for IGF-1. Cells were transfected with IGF binding
protein-3, which bound IGF-1 in the extracellular space.
This inhibited growth of Balb/c cells even in the presence
of high concentrations of insulin and IGF-1 [38]. In addi-
tion, this type of approach has been applied in the context
of the estrogen receptor, whereby neoplastic reversion
has been achieved [39].
Intracellular single-chain antibodies
In addition to antisense strategies and dominant-negative
mutations, another strategy aims at disrupting normal sub-
cellular localization of growth factor receptors. We have
recently developed an approach that prevents growth
factor receptors from reaching the cell surface. By trans-
fecting human ovarian cancer cells with a gene encoding
an anti-ErbB-2 single-chain variable fragment antibody
(sFv), we were able to demonstrate downregulation of cell
surface ErbB-2 and a corresponding specific growth inhibi-
tion of cells overexpressing the receptor [40,41••]. This
sFv-mediated oncogene downmodulation triggered apop-
totic cell death in cells that overexpress the receptor [42].
Furthermore, it could be shown that breast cancer cells
that overexpressed ErbB-2 were also eradicated in this
manner [43]. Interestingly, the level of ErbB-2 that charac-
terized breast cancer tumor targets was predictive of their
response to this genetic intervention. The ability to accom-
plish selective abrogation of oncogenes by the use of intra-
cellular sFvs opens a wide variety of possibilities in breast
cancer investigation and therapy. These results were cor-
roborated by Hynes and coworkers, who demonstrated
ErbB-2 downregulation with impairment of receptor activa-
tion in breast cancer cells [44] and reversion of the trans-
formed phenotype in ErbB-2 overexpressing cells [45].
Strategies for gene delivery
As for all mutation compensation approaches, the delivery
context is an important predicate of the viability of the
genetic intervention. In this regard, contexts whereby target
cells can be manipulated ex vivo may allow the achieve-
ment of a level of specificity and efficiency of gene delivery
that is commensurate with a meaningful therapeutic
outcome. Thus, in the context of carcinoma of the breast it
may be rational to employ such an ex vivo approach to
achieve genetic purging of bone marrow, as has been
attempted in a variety of neoplastic contexts [46,47].
Alternatively, locoregional and disseminated disease
require direct in vivo delivery of the knockout gene. Thisdelivery context imposes a greater stringency, and current
generation vectors are limited in their ability to achieve this
goal [48,49•,50,51]. In this regard, such in vivo gene
delivery approaches have been limited to disease contexts
whereby tumor is sequestered in a compartment context.
On this basis, the relatively limited presentation of breast
cancer in this manner, combined with vector limitations in
this regard, have restricted direct clinical application of
genetic ablation strategies for carcinoma of the breast.
This recognition has led to the exploration of vector
approaches that possess the capacities for efficient, and
cell-specific gene delivery in vivo. Such systems, based
on both viral and nonviral schemes, have been attempted
[52–54]. Thus, despite the fact that genetic ablation
strategies offer the possibility of a tumor cell-specific
effect, this utility can not be realized until vector
approaches can achieve a requisite level of efficiency in
the stringent in vivo gene delivery context.
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